China-based Corxel Pharmaceuticals (CORXEL) has announced a significant licensing agreement with domestic firm Vincentage, securing global development and commercialization rights to CX11 (also known as VCT220), an oral small molecule glucagon-like peptide-1 receptor agonist (GLP-1 RA), excluding Greater China. The financial details of the agreement have not been disclosed.
CX11: An Oral GLP-1 RA for Cardiometabolic Diseases
CX11 is an investigational oral small molecule GLP-1 RA designed for the treatment of cardiometabolic diseases such as obesity and type 2 diabetes. GLP-1 RAs are recognized for their ability to reduce bodyweight, enhance insulin sensitivity, and decrease glucose levels and overall appetite. The once-daily oral formulation of CX11 offers potential convenience and accessibility to patients, along with reduced manufacturing costs compared to injectable alternatives.
Phase II Study Results and Upcoming Clinical Trials
Encouraging results from a Phase II study conducted in China have shown that CX11 can achieve competitive weight loss with favorable safety and tolerability profiles. Building on these results, a regulatory Phase III study in obese and overweight patients commenced last month in China. Additionally, a global Phase II study, excluding Greater China, is planned to start next year, further expanding the clinical development of CX11 for the benefit of patients worldwide.-Fineline Info & Tech
